TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04999904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uneven Treadmill Intervention
Description: Progressive proprioceptive training on the uneven treadmill with up to twelve training sessions. Subjects will be advanced through activities with progression pragmatically assessed by the physical therapists for the benefit and tolerance of the individual subject. Activities may include: slow walking, fast walking, inclined/declined walking, head turning, vision obstruction, dual task walking, fatigued walking, load carriage. Standard of care physical therapy is still provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Physical Therapy
Description: Standard of Care Physical Therapy
Study: NCT06118216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rectus abdominis(RAM) and external oblique muscle(EOM) infiltration analgesia
Description: After suturing the muscular fascia, an indwelling catheter was placed above the RAM and EOM and under the subcutaneous tissue and then sutured to the skin for fixation. Approximately 30 min before surgery completion, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter for IA. Additionally, 1 mg/kg of 0.2% ropivacaine was infused through the indwelling catheter every 12 h, starting 8 h postoperatively, injected four times.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravenous patient-controlled anesthesia
Description: After completion of the operation, the anesthesiologist used the IPCA device; it was programmed with a background infusion rate of 2 mL/h, a bolus volume of 2 mL, and a lockout interval of 15 minutes. The 100 mL total volume of the PCA consisted of normal saline, 2.0 ug/kg sufentanil, and adjuvant antiemetic (tropisetron).
Study: NCT06029049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Time Principle Induction (MTPI) with rocuronium
Description: Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the discretion of the care team, administered within 10 seconds of rocuronium and the intubation will be performed with a C-MAC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RSI succinylcholine
Description: Participants will be induced as per routine care using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, propofol 1-2 mg/kg IV, and succinylcholine 1mg/kg IV, and the intubation will be performed with a C-MAC
Study: NCT06310421

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening SMA test
Description: Drops of blood from a puncture from the newborn's heel are collected, dried for 24 hours at room temperature and then sent to the laboratory for analysis. The screening test is a first-level molecular genetic test that allows the identification of patients affected by SMA who present the homozygous deletion of exon 7 of the SMN1 gene using the Real Time polymerase chain reaction (PCR) technique. This qualitative method is based on the use of specific fluorescent probes that discriminate the SMN1 gene from its survival motor neuron 2 (SMN2) homologue and also allow the quality assessment of genomic DNA through amplification of an internal control gene. When a positive testing patient is identified, the birth center is promptly notified to call the family and carry out a further blood sample aimed at confirming the possible diagnosis with a second level test.
Study: NCT04992663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO glasses and controller with BirthVR
Description: PICO glasses will be used for VR in the intervention group. BirthVR is a guided meditation VR application designed by qualitative research (VIREL study) performed by this study group.~The BirthVR application contains the following components:~* Information/introduction video (including a virtual reality tour through the labour ward of the Zuyderland MC)~* Fase 1: Beach environment, guided meditation/breathing exercise (1 session: 25 minutes)~* Fase 2: Underwater environment, guided meditation/breathing exercise (1 session: 25minutes)~* Fase 3: Mountain environment, breathing technique exercise on demand by using the controller (1 session: 30 minutes)~* Counseling video (cesarean section, epidural anesthesia)
Study: NCT05337800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stress managment program
Description: A four-session stress management program will be applied to the experimental group students.
Study: NCT06170853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with augmented reality glasses
Description: Three days a week (12 weeks in total), each session will be 60 minutes in total, and moderate exercise will be done with AR glasses.
Study: NCT06113211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Narcotic pain medication
Description: Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonnarcotic pain medications
Description: Primary intervention is pain medication received postoperatively. Control group will receive the standard of care which is opioid medications. Experimental group will receive a nonopioid pain control regimen.
Study: NCT05911334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROADE Program
Description: Outpatient Behavioral Intervention for Eating Disorder
Study: NCT06118216

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: intravenous patient-controlled anesthesia
Description: After completion of the operation, the anesthesiologist used the IPCA device; it was programmed with a background infusion rate of 2 mL/h, a bolus volume of 2 mL, and a lockout interval of 15 minutes. The 100 mL total volume of the PCA consisted of normal saline, 2.0 ug/kg sufentanil, and adjuvant antiemetic (tropisetron).
Study: NCT05487300

Intervention type: DRUG
Group type: OTHER
Intervention: Autonomic testing on and off levodopa
Description: Participants with Parkinson's disease with and without orthostatic hypotension will undergo standardized autonomic testing on two separate days on levodopa and off levodopa.
Study: NCT06270550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Movement Intervention
Description: Dynamic movement intervention is a physical therapy approach for infants suffering abnormal developmental motor evolution caused by a known or unknown non-degenerative syndrome affecting the central nervous system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Movement Intervention
Description: Dynamic movement intervention is a physical therapy approach for infants suffering abnormal developmental motor evolution caused by a known or unknown non-degenerative syndrome affecting the central nervous system
Study: NCT05418101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS171
Description: Participants will receive VIS171 via SC route of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS171
Description: Participants will receive VIS171 via SC route of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS171
Description: Participants will receive VIS171 via SC route of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS171
Description: Participants will receive VIS171 via SC route of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS171
Description: Participants will receive VIS171 via SC route of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS171
Description: Participants will receive VIS171 via SC route of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS171
Description: Participants will receive VIS171 via SC route of administration.
Study: NCT06149559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozanolixizumab
Description: rozanolixizumab solution for injection
Study: NCT06003686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PVA Consumer Guide
Description: Subject's will receive education on the PVA consumer guide 3 times over the course of the study.~Each session will be approximately 10-15 minutes and will consist of a general review of the nutrition, exercise, and general healthy living guidelines content included.
Study: NCT05775016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 week resistance and cardiovascular exercise program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 week resistance and cardiovascular exercise program
Study: NCT05418101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS171
Description: Participants will receive VIS171 via SC route of administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo via SC route of administration
Study: NCT05775016

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: 12 week resistance and cardiovascular exercise program
Study: NCT05375227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teeth brushing
Description: The participants will be invites to brush their teeth twice a day for 3 months using either an electric toothbrush or a mannual toothbrush and low abrasivity toothpaste
Study: NCT05418101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo via SC route of administration
Study: NCT05375227

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teeth brushing
Description: The participants will be invites to brush their teeth twice a day for 3 months using either an electric toothbrush or a mannual toothbrush and low abrasivity toothpaste
Study: NCT05418101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo via SC route of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo via SC route of administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo via SC route of administration
Study: NCT06371027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane
Description: Minimally Invasive Surgery Technique (MIST) + Novel Silk Fibroin (SF) nanofiber membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Surgery Technique (MIST) + collagen membrane
Description: Minimally Invasive Surgery Technique (MIST) + collagen membrane placement in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Surgery Technique (MIST)
Description: Minimally Invasive Surgery Technique in the area that contains an intraosseous defects with Probing depth (PD) ≥5 mm
Study: NCT06214910

Intervention type: OTHER
Group type: OTHER
Intervention: Community-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP)
Description: Participants randomized to this arm will receive the entire supply of TB preventive therapy (TPT) at enrollment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-link TPT
Description: Participants receive 2-week supply of TPT at initiation, then continue to receive remainder of TPT course at clinic (including refills).
Study: NCT06442111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The intravenous ferritin group
Description: Administer intravenous ferritin approximately 3-7 days before surgery (0.9% normal saline 250ml + 1000 mg of ferric carboxymaltose \[Ferinject™, Vifor Pharma, Glattbrugg, Dwitzerland\], inject over 15 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The intravenous ferritin group
Description: Administer intravenous ferritin approximately 3-7 days before surgery (0.9% normal saline 250ml + 1000 mg of ferric carboxymaltose \[Ferinject™, Vifor Pharma, Glattbrugg, Dwitzerland\], inject over 15 minutes)
Study: NCT06499402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: sacral massage
Study: NCT06003686

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WebMD
Description: Subject's will receive education on how to navigate the WebMD site and find information on health, exercise and nutrition 3 times over the course of the study. Each session will be approximately 10-15 minutes and will consist of a general review of the health and wellness content available on the website. At study completion, subjects in this group will be provided with the PVA guide and a brief orientation of the nutrition, exercise, and general healthy living guidelines content included in the guide.
Study: NCT06442111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The placebo group
Description: Administer intravenous 10ml of normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) approximately 3-7 days before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The placebo group
Description: Administer intravenous 10ml of normal saline (Isotonic Sodium Chloride Injection Daihan(50mL/bag)) approximately 3-7 days before surgery
Study: NCT05201898

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control:usual medical management
Description: with regular doctor visits every 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control:usual medical management
Description: with regular doctor visits every 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control:usual medical management
Description: with regular doctor visits every 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention 1:usual medical management+individual dieting consultation
Description: with regular doctor visits every 3 months and dietitian visits every 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention 1:usual medical management+individual dieting consultation
Description: with regular doctor visits every 3 months and dietitian visits every 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention 2:usual medical management+individual dieting consultation+ daily tea drinking
Description: with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking
Study: NCT05376657

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry collagen drink
Description: consume 1 sachet per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: consume 1 sachet per day
Study: NCT06466460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion based - Virtual cycling
Description: To examine whether the activity of virtual cycling contributes to the improvement of quality of life for individuals with cognitive impairment. (Intervention study)
Study: NCT05617144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy treatment
Description: 60 minutes after pain medication administration primary investigator will turn on the diffuser (manufacture ScentSationals)and administer aromatherapy with a mixture of four drops of lavender and four drops of peppermint for 60 minutes.
Study: NCT06531486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XS-02 capsules
Description: Upon completion of all screening visits, eligible patients will be treated with XS-02 capsules at the appropriate dose.
Study: NCT05362929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sciton Halo
Description: Laser treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sciton Halo
Description: Laser treatment
Study: NCT05052190

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message R/R with Direct Appointment Schedule Link
Description: Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message R/R with Direct Appointment Schedule Link
Description: Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine with a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message R/R without Direct Appointment Schedule Link
Description: Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.
Study: NCT05116410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20094
Description: Administrated SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20094
Description: Administrated SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administrated SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administrated SC
Study: NCT04657861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APRIL CAR-T cells
Description: Each subject receive APRIL CAR T-cells by intravenous infusion
Study: NCT04798898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA (radiofrequency ablation)
Description: Preoperative RFA-induced partial necrosis of the liver metastasis
Study: NCT05569525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal therapy
Description: Non-surgical periodontal therapy according to the full-mouth debridement protocol.
Study: NCT05052190

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message R/R without Direct Appointment Schedule Link
Description: Participants in this arm will receive up to 3 R/R messages by text reminding them to get a flu vaccine without a Direct Appointment Scheduling link and instructions to make a flu vaccine appointment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Pre-Appointment Reminder
Description: Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period advising them to get the flu vaccine at their upcoming appointment.
Study: NCT05569525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Description: Non-surgical periodontal therapy according to the full-mouth debridement protocol.
Study: NCT05699603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo skin biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene
Description: Applied topically
Study: NCT05572983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combined with CHOP
Description: A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide: 20mg，qw（d1,d4）,po
Study: NCT05421208

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controls
Description: Inflammatory and immune profile of post-COVID-19 POTS patients. Reduced PNS activity (vagal tone) in relation to persistent inflammation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Levels of inflammatory cytokine ( IL-6) in controls
Description: Inflammatory and immune profile of healthy controls. Controls are the subjects who recovered from COVID-19 infection with no sequelae.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Effect on inflammation after chronic PNS stimulation
Description: Inflammatory biomarkers after restoring PNS function in post-COVID-19 POTS patients, by chronic transcutaneous vagus nerve stimulation (tVNS) in post COVID-19 POTS patients
Study: NCT06146166

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral herbal supplement
Description: Oral supplement containing an oral blend taken once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo supplement
Description: Oral placebo supplement taken once daily
Study: NCT05699603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Applied topically
Study: NCT05473234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Children enrolled in the trial and randomized to receive azithromycin will receive a single dose of azithromycin at 20 mg/kg up to the maximum adult dose of 1g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Children enrolled in the trial and randomized to receive amoxicillin will receive a 5-day course of amoxicillin to be given in twice-daily doses of 15 mg/kg per the Nigeria guidelines for severe acute malnutrition. The first dose will be administered at the time of enrollment, and the remaining doses will be administered by the caregiver at home. Enrolled children will also receive RUTF.
Study: NCT04753606

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obicetrapib
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obicetrapib
Description: tablets
Study: NCT04938869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive basic diabetes mellitus education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Use CGM device and app
Study: NCT05052190

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Pre-Appointment Reminder
Description: Participants will receive a Pre-Appointment Reminder via text when they schedule a visit during the study period advising them to get the flu vaccine at their upcoming appointment.
Study: NCT04938869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06615635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DaRT seeds
Description: Diffusing Alpha emitters Radiation (DaRT) treatment to be delivered through radioactive sources inserted into malignant cutaneous squamous cell carcinoma of Immunocompromised Patients